People news: Savient and Lilly Oncology

Share this article:
John Johnson, SVP and president of Lilly Oncology, has resigned from the company effective January 28. He will join New Jersey-based Savient Pharmaceuticals as the company's CEO, effective January 31. Johnson's decision to resign was “driven by personal and family considerations,” according to a Lilly statement. Johnson, formerly CEO of ImClone, became SVP and president of Lilly Oncology following Lilly's acquisition of ImClone in 2008. Prior to ImClone, Johnson served as company group chairman of J&J's worldwide biopharmaceuticals unit.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media